Amgen Inc. (NASDAQ:AMGN) Shares Sold by Sender Co & Partners Inc.

Sender Co & Partners Inc. cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 41.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,272 shares of the medical research company’s stock after selling 883 shares during the quarter. Amgen makes up approximately 0.5% of Sender Co & Partners Inc.’s portfolio, making the stock its 27th biggest position. Sender Co & Partners Inc.’s holdings in Amgen were worth $397,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Lighthouse Investment Partners LLC purchased a new stake in shares of Amgen in the 2nd quarter valued at approximately $15,155,000. Marathon Capital Management increased its holdings in Amgen by 30.1% in the second quarter. Marathon Capital Management now owns 1,188 shares of the medical research company’s stock valued at $371,000 after buying an additional 275 shares during the last quarter. MBB Public Markets I LLC raised its stake in Amgen by 54.0% in the second quarter. MBB Public Markets I LLC now owns 75,712 shares of the medical research company’s stock valued at $23,656,000 after buying an additional 26,553 shares in the last quarter. Daymark Wealth Partners LLC lifted its holdings in Amgen by 1.5% during the 2nd quarter. Daymark Wealth Partners LLC now owns 228,195 shares of the medical research company’s stock worth $71,300,000 after buying an additional 3,299 shares during the last quarter. Finally, Delta Investment Management LLC lifted its holdings in Amgen by 3.3% during the 2nd quarter. Delta Investment Management LLC now owns 1,903 shares of the medical research company’s stock worth $595,000 after buying an additional 61 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on AMGN shares. Royal Bank of Canada restated an “outperform” rating and set a $362.00 target price on shares of Amgen in a research note on Thursday. Oppenheimer reissued an “outperform” rating and set a $380.00 price objective on shares of Amgen in a report on Wednesday, August 7th. Robert W. Baird restated an “underperform” rating and set a $215.00 price objective on shares of Amgen in a research report on Wednesday. Jefferies Financial Group reiterated a “buy” rating and set a $380.00 price target (up from $375.00) on shares of Amgen in a research note on Wednesday, August 7th. Finally, Morgan Stanley decreased their price objective on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research note on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Amgen presently has an average rating of “Moderate Buy” and an average price target of $321.37.

Amgen Stock Performance

NASDAQ:AMGN opened at $319.10 on Friday. The firm has a market cap of $171.18 billion, a price-to-earnings ratio of 45.59, a price-to-earnings-growth ratio of 2.98 and a beta of 0.61. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. Amgen Inc. has a 1-year low of $249.70 and a 1-year high of $346.85. The firm’s fifty day moving average price is $328.94 and its 200 day moving average price is $307.00.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The firm had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. The company’s revenue was up 20.1% compared to the same quarter last year. During the same quarter last year, the firm earned $5.00 earnings per share. On average, sell-side analysts expect that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were issued a $2.25 dividend. The ex-dividend date was Friday, August 16th. This represents a $9.00 annualized dividend and a dividend yield of 2.82%. Amgen’s dividend payout ratio is currently 128.57%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.